<!DOCTYPE html>
<html>

<!-- Mirrored from mullinslab.microbiol.washington.edu/publications/729-Three-main-mutational-pathways-in-HIV-2-lead-to-high-level-raltegravir-and-elvitegravir-resistance-implications-for-emerging-HIV-2-treatment-regimens by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 21 Jul 2025 18:06:09 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    
<title>Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. | Mullins Molecular Retrovirology Lab</title>

    
    <link rel="stylesheet" href="style.css" />
    
    <link rel="alternate" type="application/atom+xml" title="Atom feed" href="feed" />
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML' async></script>

    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-136625084-1"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'UA-136625084-1');
    </script>
</head>
<body id="entry">

<div id="container">

<header>

<h1>Mullins Molecular Retrovirology Lab</h1>

<div class="description">
<ul>
<li>Department of Microbiology</li>
<li>School of Medicine</li>
<li>University of Washington</li>
</ul>

</div>


</header>

<section id="nav">
    <nav>
        
        <ul>
            <li class=""><a href="../index.html">Home</a></li>
            <li class=""><a href="../research/index.html">Research</a></li>
            <li class="here"><a href="index.html">Publications</a><ul><li><a href="supplemental.html">Supplemental Data</a></li></ul></li>
            <li class=""><a href="../protocols/index.html">Protocols</a></li>
            <li class=""><a href="../people/index.html">People</a></li>
            <li class=""><a href="../contact/index.html">Contact</a></li>
            <li class=""><a href="../help/index.html">Help</a></li>
        </ul>
    </nav>
</section>

<section id="links">
    <nav id="quicklinks">
        <h2>Software &amp; Tools</h2>

        <ul>
            <li><a href="http://indra.mullins.microbiol.washington.edu/">Bioinformatics Tools</a></li>
            <li><a href="https://github.com/mullinslab">GitHub</a></li>
            <li><a href="../hiris/index.html">HIRIS</a></li>
            <li><a href="../HMA/index.html">HMA Subtyping Kit</a></li>
            <li><a href="../isdb/index.html">ISDB</a></li>
            <li><a href="../tcozy/index.html">TCozy</a></li>
            <li><a href="https://viroverse.washington.edu/">Viroverse</a></li>
        </ul>
    </nav>

    <nav id="lablinks">
        <h2>Lab Links</h2>

        <ul>
            <li><a href="https://hercules.mullins.microbiol.washington.edu/pub/doc/">Computing Docs</a></li>
            <li><a href="../hiris/private/index.html">HIRIS (Private)</a></li>
            <li><a href="https://tcozy.mullins.microbiol.washington.edu/ice-floe/">ICE Floe</a></li>
            <li><a href="https://hercules.mullins.microbiol.washington.edu/git/">Internal Git</a></li>
            <li><a href="../twiki/index.html">Internal wiki</a></li>
            <li><a href="https://viroverse.washington.edu/viroblast/">Local ViroBLAST</a></li>
            <li><a href="https://redash.mullins.microbiol.washington.edu/">Redash</a></li>
            <li><a href="https://mullinslab.slack.com/">Slack</a></li>
            <li><a href="../support/index.html">Ticketing system</a></li>
        </ul>
    </nav>

</section>

<div id="cfar"><a href="http://cfar.washington.edu/">
    <img src="../static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_500x157.jpg" width="500" height="157" srcset="/static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_500x157.jpg 1x, /static/_img/2c/47ca/CFAR-logo-rev-10-22-18_4aa6fe47bc_1000x314.jpg 2x" alt="University of Washington/Fred Hutch Center for AIDS Research">
</a></div>

<section id="content">
    
<!-- source file: content/publications/smith_2012-527.md -->
<article>

<div id="intro">
    <h1>Citation Information</h1>
<p>Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, Church B, Parker K, Mullins JI, Sow PS, Gottlieb GS, University of Washington-Dakar HIV-2 Study Group (2012). <span class="title">Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.</span> <cite class="journalName">PloS one</cite>, <span class="journalIssue">7(9)</span>, e45372. (<a href="http://ncbi.nlm.nih.gov/pubmed/23028968">pubmed</a>) (<a href="https://doi.org/10.1371/journal.pone.0045372">doi</a>)</p>
</div>


<div id="more">
    <h1>Abstract</h1>
<p>Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a pressing need to identify new classes of antiretroviral agents that are active against HIV-2. Although recent data suggest that the integrase strand transfer inhibitors raltegravir and elvitegravir may be beneficial, mutations that are known to confer resistance to these drugs in HIV-1 have been reported in HIV-2 sequences from patients receiving raltegravir-containing regimens. To examine the phenotypic effects of mutations that emerge during raltegravir treatment, we constructed a panel of HIV-2 integrase variants using site-directed mutagenesis and measured the susceptibilities of the mutant strains to raltegravir and elvitegravir in culture. The effects of single and multiple amino acid changes on HIV-2 replication capacity were also evaluated. Our results demonstrate that secondary replacements in the integrase protein play key roles in the development of integrase inhibitor resistance in HIV-2. Collectively, our data define three major mutational pathways to high-level raltegravir and elvitegravir resistance: i) E92Q+Y143C or T97A+Y143C, ii) G140S+Q148R, and iii) E92Q+N155H. These findings preclude the sequential use of raltegravir and elvitegravir (or vice versa) for HIV-2 treatment and provide important information for clinical monitoring of integrase inhibitor resistance in HIV-2-infected individuals.</p>
</div>


<div class="clear"></div>
</article>

</section>

</div>
</body>
<!-- Mirrored from mullinslab.microbiol.washington.edu/publications/729-Three-main-mutational-pathways-in-HIV-2-lead-to-high-level-raltegravir-and-elvitegravir-resistance-implications-for-emerging-HIV-2-treatment-regimens by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 21 Jul 2025 18:06:09 GMT -->
</html>